원문정보
초록
영어
Cardio and cerebrocascular disorders lead to about 26 million deaths every year around the world. Cardio and cerebrovaccular disorders have not only high mortality rate across the globe but also leading to subsequent complication such as thrombolysis could favorably influence the outcome of such life-threatening disorder as myocardial infarction, cerebrovascular thrombosis, and venous thromboembolism. Our healthy system is capable to overcome to these consequences but when there is imbalance of defensive and aggressive factor in our system result come as blood clot in systemic circulation. Now role of thrombolytic agents come in picture as artificial plasminogen activators that convert plasminogen, an inactive form of plasmin to dissolve the clot by converting inactive plasminogen in active plasmin. Plasmin dissolves the fibrin blood clot, but may also degrade normal components of the hemostatic system which can further create another life threatening consequence and death also so there is always need of such an agent who specifically dissolved clot which are in circulation but not others.
목차
1. Introduction
2. Thrombolysis or Fibrinolysis
3. Lumborkinase
Historical Overview:
Isolation of Lumbokinase:
Mechanism of Action:
Gene Structure of Lumbrokinase
Protein Structure of Lumbrokinase
Recombinant Lumbrokinase
4. Recent Advancement of Lumbrokinase:
Crystallization
F0F1-ATPase Micro- mixer
Immobilization and Chemical Modification
5. Clinical Application of Lumbrokinase
A Potent Fibrinolytic Agent
Protection of Cerebral Ischemia:
Assistant to Implantation
6. Discussion and Conclusion:
References
